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ABSTRACT In an attempt to assess the cross-protective potential of the influenza virus neuraminidase (NA) as a vaccine antigen,
different subtypes of recombinant NA were expressed in a baculovirus system and used to vaccinate mice prior to lethal chal-
lenge with homologous, heterologous, or heterosubtypic viruses. Mice immunized with NA of subtype N2 were completely pro-
tected frommorbidity andmortality in a homologous challenge and displayed significantly reduced viral lung titers. Heterolo-
gous challenge with a drifted strain resulted in morbidity but nomortality. Similar results were obtained for challenge
experiments with N1 NA. Mice immunized with influenza B virus NA (from B/Yamagata/16/88) displayed nomorbidity when
sublethally infected with the homologous strain and, importantly, were completely protected frommorbidity andmortality
when lethally challenged with the prototype Victoria lineage strain or a more recent Victoria lineage isolate. Upon analyzing the
NA content in 4 different inactivated-virus vaccine formulations from the 2013-2014 season viaWestern blot assay and enzyme-
linked immunosorbent assay quantification, we found that the amount of NA does indeed vary across vaccine brands. We also
measured hemagglutinin (HA) and NA endpoint titers in pre- and postvaccination human serum samples from individuals who
received a trivalent inactivated seasonal influenza vaccine from the 2004-2005 season; the induction of NA titers was statistically
less pronounced than the induction of HA titers. The demonstrated homologous and heterologous protective capacity of recom-
binant NA suggests that supplementing vaccine formulations with a standard amount of NAmay offer increased protection
against influenza virus infection.
IMPORTANCE Despite the existence of vaccine prophylaxis and antiviral therapeutics, the influenza virus continues to cause
morbidity andmortality in the human population, emphasizing the continued need for research in the field. While the majority
of influenza vaccine strategies target the viral hemagglutinin, the immunodominant antigen on the surface of the influenza vi-
rion, antibodies against the viral neuraminidase (NA) have been correlated with less severe disease and decreased viral shedding
in humans. Nevertheless, the amount of NA is not standardized in current seasonal vaccines, and the exact breadth of NA-based
protection is unknown. Greater insight into the cross-protective potential of influenza virus NA as a vaccine antigen may pave
the way for the development of influenza vaccines of greater breadth and efficacy.
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Seasonal influenza virus infections cause significant morbidityand mortality worldwide (1). If well matched to currently cir-
culating strains, influenza virus vaccines are efficient tools in pro-
tecting the human population from influenza virus infection. Al-
though effective, these vaccines have a suboptimal efficacy
(74 percent) in healthy adults for well-matched strains (2), and
this value may drop sharply when the vaccine is mismatched (3).
Furthermore, the seasonal vaccine is not protective against pan-
demic influenza viruses. Immune responses following vaccination
with inactivated influenza virus (IIV) are predominantly raised to
the viral hemagglutinin (HA), the major glycoprotein on the sur-
face of the influenza virion. The majority of antibodies are di-
rected against the immunodominant globular head domain of the
molecule (4–7). These antibodies are highly potent in inhibiting
virus replication and are often strain specific. Thus, themain focus
of influenza virus vaccine development, production, and efficacy
testing is on the HA. IIVs are standardized based on their HA
content, and vaccine efficacy is measured based on the induction
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of hemagglutination-inhibiting antibodies (8). The second influ-
enza surface glycoprotein, the neuraminidase (NA), has enzy-
matic activity that is crucial for the virus and is the target of small-
molecule NA inhibitors (9). While many studies propose the
usefulness of NA as a vaccine antigen (10–19), the viral neuramin-
idase is mostly ignored in the context of influenza vaccine devel-
opment, and the NA content of IIVs is not even measured.
Early epidemiological studies that were conducted in humans
in the 1960s and 1970s demonstrated that higher neuraminidase
inhibition (NI) titers were correlated with lower morbidity and
decreased viral shedding (10, 20, 21). Recent studies have shown
that NA-based immunity can have protective efficacy against in-
fluenza virus infection in animal models and humans (9, 16, 17,
20, 22–24). Here, we evaluated the breadth of influenza A and B
virus NA-based immunogens and their protective efficacy in the
mouse model. Furthermore, we compared the levels of induction
of anti-NA immunity and anti-HA immunity after IIV vaccina-
tion in humans and analyzed the NA content of four 2013-2014
season IIVs from different manufacturers.
RESULTS
Expression of recombinant NA proteins. Influenza virus NA has
been found to be immunosubdominant when administered in
association with the influenza virus HA in animal models (30, 31,
32). We therefore chose to investigate the protective efficacy and
breadth of divergent NAs using baculovirus-expressed antigens.
These recombinant NAs (rNAs) include an N-terminal hexahisti-
dine tag to facilitate purification and a tetramerization domain to
guarantee optimal folding and are secreted into the cell superna-
tant, allowing posttranslational modification to occur in the en-
doplasmic reticulum and in the Golgi network (26, 27). All NAs
were obtained at high purity and exhibited enzymatic activity (see
Fig. S1 and S2 in the supplemental material). Their expression
levels varied between approximately 0.1 and 5 mg/liter of culture.
Recombinant influenza virus NA immunogens protect mice
from homologous virus challenge. To assess the protective effi-
cacy of subtype N1, N2, and influenza B virus NAs, mice were
vaccinated twice at a 3-week interval with N1 NA from PR8, N2
NA fromHK68/X-31, or influenza B virus NA from Yam88 B (see
Materials and Methods for descriptions of viruses). The vaccines
were administered intramuscularly (i.m.) and intranasally (i.n.)
[5 g adjuvanted with 5 g of poly(I · C) each] because the con-
tribution ofmucosal versus systemic immunity forNA-based pro-
tection was unclear. Four weeks postboost, the animals were chal-
lenged with 10 murine 50% lethal doses (mLD50) of homologous
virus or 1.1 106 PFU forYam88B.Animals that receivedPR8N1
were fully protected from weight loss and mortality, comparable
to the results for the positive-control animals, which received in-
activated matched whole-virus vaccine (Fig. 1A and D), while
control animals vaccinated with bovine serum albumin (BSA) or
recombinant N2 (rN2) lost weight rapidly and succumbed to in-
fection by day 8 or 9 postinfection, respectively. Similarly, animals
vaccinated with HK68/X-31 N2 were completely protected from
homologous lethal HK68/X-31 challenge, while control animals
(BSA and rN1 vaccinated) lost weight and succumbed to infection
by day 7 (Fig. 2A and C). N2 vaccination significantly reduced
virus infection in the lungs of these mice on day 3 postinfection,
and only one of five mice had detectable amounts of virus in the
lungs on day 6 postinfection (Fig. 3B). N2 vaccination did not
induce sterilizing immunity, as did two vaccinations with inacti-
vated homologous virus, but it reduced lung titers 1,000-fold on
day 3 and 100,000-fold on day 6 compared to the lung titers in the
BSA control group. Finally, vaccination with Yam88 B recombi-
nant NA completely protected mice against a nonlethal challenge
with Yam88 B, while control animals (BSA and rN2 vaccinated)
lost approximately 20% of their initial weight and had survival
rates of only 80% (Fig. 4A and D), showing that influenza B virus
NA is as protective as influenza A virus NA.
Protection is mediated by NA-reactive antibodies. To inves-
tigate the mechanism of protection, we measured anti-NA titers
using enzyme-linked immunosorbent assays (ELISA) with puri-
fied whole virus as the substrate. In all three cases, we could detect
high levels of reactivity against the homologous virus (Fig. 1G, 2E,
and 4G). To assess the functionality of this antibody response, we
determined NI titers against the respective homologous viruses
using the enzyme-linked lectin assay (ELLA) and found a high
level of activity in all three cases (Fig. 1J, 2G, and 4J). To confirm
the role of antibodies as a contributing mechanism of protection,
we performed a passive transfer challenge experiment. Sera from a
positive-control group vaccinated twice with HK68/X-31 inacti-
vated whole-virus vaccine, a group that received rN2, and a group
that received BSA were transferred into three sets of naive mice,
respectively. Two hours posttransfer, the animals were challenged
with 5 mLD50 of HK68/X-31 virus. No difference in weight loss
was observed between rN2-serum-treated and positive-control
mice: both groups showed modest weight loss of approximately
10%of their initial weight and allmice in both groups survived the
infection, while control mice lost weight rapidly and succumbed
to infection on day 8 postchallenge (Fig. 3A).
Mucosal NA vaccination confers better protection than in-
tramuscular NA vaccination. Mechanistically, NA antibodies
may affect at least two important steps of the influenza virus life
cycle. It is well established that the activity of NA is important for
virus release from infected cells (9). However, there is also evi-
dence that NA is necessary for the successful transport of incom-
ing virus particles throughmucins on themucosa (9, 33).Wewere
therefore interested to compare the efficacy of intramuscular ver-
sus intranasal vaccination, since the latter also induces mucosal
antibodies. Mice were vaccinated twice with rN2 at a 3-week in-
terval intranasally or intramuscularly [5 g rN2 plus 5 g of
poly(I · C) per dose]. Control animals received BSA (i.n. and i.m.)
or recombinant N1 (rN1) via i.n. or i.m. administration. At 4
weeks postvaccination, mice were challenged with 10 mLD50 of
HK68/X-31. Although a small difference in weight loss could be
observed on days 4 to 7 postvaccination, no statistically significant
difference between the i.n. and i.m. routes could be established
(Fig. 3C). All rN2-vaccinated animals (for both i.n. and i.m. vac-
cination) survived the infection, while all control animals suc-
cumbed to infection between days 6 and 7, regardless of the vac-
cination route. We then repeated the experiment with a higher
challenge dose of 25 mLD50 and found that i.n. vaccination pro-
tected mice from weight loss significantly better than i.m. vacci-
nation did (Fig. 3D). However, the systemic anti-N2 IgG antibody
levels were similar in the three experimental groups, suggesting an
important role of mucosal immunity—most likely mucosal
IgA—in NA-based protection (Fig. 3E).
NA immunogens partially protect against heterologous but
not against heterosubtypic influenzaAvirus challenge.Next, we
wanted to assess the breadth of protection that NA-based immu-
nity can afford. To look at the breadth of N1 immunity, we again
Wohlbold et al.
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FIG 1 Vaccination with recombinant N1 protects mice from homologous and heterologous viral challenge. (A to C) Six- to 8-week-old naive BALB/c mice
(n 5 for PR8 N1 group and N2 control group; n 10 for negative-control group and positive-control groups) were primed and boosted with 10g rNA from
PR8 (5 g delivered i.m. and 5 g delivered i.n.) adjuvanted with poly(I · C). Negative-control mice were primed and boosted with 10 g BSA (5 g delivered
i.m. and 5g delivered i.n.) adjuvantedwith poly(I · C). Positive-controlmice received a 1-g i.m. prime and boost of a formalin-inactivated, unadjuvanted virus
matching the challenge strain. Additionally, one experimental group was primed and boosted with rN2 in a fashion identical to the method used for the
N1-vaccinatedmice. Upon challenge, weight loss wasmonitored for 14 days postinfection as ameasure of morbidity. Graphs plot the average amounts of weight
loss as percentages of initial weight with standard deviation (SD). (D to F) Survival curves from the challenge experiments whose results are shown in panels A
to C. (G to I) Pooled sera from individual mice (PR8 N1 vaccinated, rN2 vaccinated, or naive) in each experimental group were tested in triplicate for reactivity
to purified virus via ELISA. (J to L) The same sera used in the experiment whose results are shown in panels G to I were tested in triplicate for NI activity against
the respective challenge viruses. *, positive-control data shown in panels C and F were collected from the high-challenge-dose group (10mLD50). n 5mice per
group unless otherwise stated.
Inﬂuenza Virus Neuraminidase-Based Cross-Protection
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FIG 2 Vaccination with recombinant N2 protects mice from homologous and heterologous viral challenge. The experimental design for these challenge studies
was identical to that detailed in the legend to Fig. 1, except that mice (n  5 per group) were primed and boosted with rNA from HK68/X-31 (H3N2) and
challenged with homologous H3N2 reassortant strain HK68/X-31 or the heterologous H3N2 strain Phil82/X-79. Control mice were primed and boosted with
rNA from PR8 or BSA. (A to D) Weight loss and survival of mice challenged with HK68/X-31 (A and C) or Phil82/X-79 (B and D). (E to G) Pooled sera from
individualmice (HK68/X-31N2 vaccinated, rN1 vaccinated, or naive) in each experimental groupwere tested in triplicate both for reactivity to purified virus via
ELISA (E and F) and for NI activity against HK68/X-31 (G) and Phil82/X-79 (H).
Wohlbold et al.
4 ® mbio.asm.org March/April 2015 Volume 6 Issue 2 e02556-14
 
m
bio.asm
.org
 o
n
 D
ecem
ber 30, 2015 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
FIG 3 Passive transfer of sera from vaccinated mice and i.m. versus i.n. vaccination. To demonstrate that humoral immunity against NA is sufficient for
protection, passive transfer experiments were performed. Sera from animals vaccinated with HK68/X-31 N2, inactivated whole HK68/X-31 virus, or BSA were
transferred into naive mice, which were subsequently challenged with HK68/X-31 virus. (A)Weight loss postchallenge. All mice that received HK68/X-31 N2 or
the inactivated whole-virus vaccine survived the challenge. (B) Lung titers of virus in animals vaccinated with HK68/X-31 N2, BSA, or inactivated whole
HK68/X-31 virus on day 3 and day 6 postchallenge with HK68/X-31. (C and D) To assess whether the route of vaccine administration had an impact on
protection, a challenge experiment identical to the onewhose results are shown in Fig. 2Awas performed, except that themice in one group (n 10)were primed
andboostedwith 10gN2 [adjuvantedwith poly(I · C)] exclusively intramuscularly (i.m.), while those in the other (n 10)were primed andboosted exclusively
intranasally (i.n.). Initially, there was a slight but not very distinguishable difference in weight loss (C); however, upon repeating the experiment with a higher
challenge dose (25 LD50), a clear difference in the percentages of weight lost was seen, with the i.n.-vaccinated mice displaying significantly less weight loss than
the i.m.-vaccinated mice (D). Survival was 100% in both groups. (E) Reactivities to HK68/X-31 virus were similar for mice that received HK68/X-31 N2 via the
i.m. route, the i.n. route, or both at the same time (i.m.i.n.). n.s., not significant; P 0.05; *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001. n 5mice
per group unless otherwise stated.
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FIG 4 Vaccination with recombinant influenza B virus NA protects mice from homologous and heterologous viral challenge. The experimental design for these
challenge studies was identical to those whose results are shown in Fig. 1 and 2, except that mice (n  5 per group) were primed and boosted with rNA from
Yam88 B and challenged with the homologous Yam88 B virus or the heterologous influenza B virus strains Vic87 andMal04. The mice in the N2 control group
were primed and boosted with rNA from HK68/X-31. (A to F) Weight loss and survival after homologous challenge with Yam88 B (A and D) or heterologous
challenge with Vic87 (B and E) or Mal04 (C and F). (G to I) Seroreactivities of influenza B virus Yam88 B NA-vaccinated mice to Yam88 B (G), Vic87 (H), or
Mal04 (I) virus. (J to L) The same sera used in the experiment whose results are shown in panels G to I were tested in triplicate forNI activity against the respective
challenge viruses.
Wohlbold et al.
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vaccinated animals with PR8 N1 but then challenged them with 5
mLD50 of either NL09 H1N1 (2009 pandemic strain) or VN04
H5N1. Both viruses carry N1 NAs that belong to a different N1
clade than PR8 N1, which falls into the human N1 clade (9). PR8
N1 was able to provide partial protection against weight loss
(compared to the results for BSA and N2 control animals) and
mortality (80% survival in both cases) (Fig. 1B, C, E, and F). How-
ever, when challenged with a higher dose of 10 mLD50 of NL09
virus, all PR8 N1-vaccinated mice succumbed to infection, show-
ing the limit of cross-protection (data not shown). Specific reac-
tivity to purified NL09 and VN04 virus particles could be detected
by ELISA and might explain the observed cross-protection
(Fig. 1H and I). However, only a low level of specific NI activity
against NL09 could be detected and no activity above the back-
ground level was detected for VN04 (Fig. 1K and L). Cross-
reactivity of N2 was tested using the heterologous Phil82/X-79
H3N2 strain that is separated from HK68/X-31 by 14 years of
antigenic drift. Animals challenged with a 5 mLD50 dose of virus
were completely protected from mortality but showed a body
weight loss of approximately 80% (Fig. 2B and D). With a higher
challenge dose of 10 mLD50, survival dropped to 20% (data not
shown). HK68/X-31 N2 sera showed low levels of specific cross-
reactivity to Phil82/X-79 virus in ELISA and detectable but low
levels of NI activity (Fig. 2F and H).
In the experiments described above, we used rN2-vaccinated
mice as controls for challenge with viruses expressing N1NAs and
vice versa without observing protection in the controls. This indi-
cated the absence of heterosubtypic immunity between N1 and
N2. However, there are currently nine true influenza A virus NA
subtypes known (those with demonstrated NA enzymatic activ-
ity), and it was unclear whether any of them would share protec-
tive epitopes with either N1 or N2 NA. To explore this, we vacci-
nated mice twice with rN3, rN4, rN5, rN6, rN7, rN8, or rN9 NA
and challenged them with 5 mLD50 of either PR8 (H1N1) or
HK68/X-31 (H3N2). All animals seroconverted to the respective
NAs (see Fig. S3 in the supplemental material) but lost weight
rapidly after infection with PR8 (Fig. 5A) or HK68/X-31 (Fig. 5B).
Survival was 0% in most cases, but in the rN5 and rN7 PR8 chal-
lenge groups and the rN6 HK68/X-31 challenge group, survival
was 20% (one animal). However, survival of a low percentage of
animals is expected with a challenge dose of 5 mLD50. Our con-
clusion from these experiments is that vaccination with influenza
A virus NA does not induce heterosubtypic immunity.
Vaccinationwith influenzaBvirusNA inducesbroadprotec-
tion against heterologous virus challenge. The genetic diversity
of influenza B virus HAs and NAs is limited compared to the
genetic diversity of influenza A virus HAs and NAs (9, 34). To
assess the breadth of NA-based immunity against influenza B vi-
ruses, we vaccinated animals with NA from Yam88 B, the lineage-
defining strain of the Yamagata lineage. We then challenged these
animals with influenza B viruses Vic87 and Mal04, both of which
belong to the antigenically distinct (based on HA) Victoria lin-
eage. Interestingly, vaccination with Yam88 B NA protected
against weight loss andmortality after challenge with the two het-
erologous strains (Fig. 4B, C, E, and F). NA cross-reactivity could
be detected against both viruses, although the level of reactivity to
FIG 5 Vaccination with rNA does not induce heterosubtypic immunity in mice. To test the possibility of NA-induced heterosubtypic cross-protection, a
sizeable challenge study was performed in which mice were separated into groups (n 5) and primed and boosted with representative rNAs from subtypes N3
to N9. Similar to the experiment whose results are shown in Fig. 1, animals received identical primes and boosts of 10 g rNA (5 g delivered i.m. and 5 g
delivered i.n.) adjuvanted with poly(I · C). Negative-control mice were primed and boosted with 10 g BSA (5 g delivered i.m. and 5 g delivered i.n.)
adjuvanted with poly(I · C). No reduction in weight loss was observed upon lethal (5 LD50) challenge with PR8 (A) or HK68/X-31 (B). (C andD) Survival curves
from the challenge experiments whose results are shown in panels A and B. No appreciable protection from mortality was observed.
Inﬂuenza Virus Neuraminidase-Based Cross-Protection
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Vic87 was higher than the level of reactivity toMal04 (Fig. 4H and
I). Yam88 B NA vaccination induced robust NI titers against
Vic87 (Fig. 4K). The NI activity against Mal04 was low but still
detectable (Fig. 4L).
IIV does not efficiently induce N1 and N2 reactive antibody
responses inhumans.Next,wewanted to evaluate the response to
HA and NA in the context of seasonal IIV vaccination in humans.
Although earlier studies have indicated that the anti-NA response
to IIV in humans is low, we wanted to assess this using a quanti-
tative ELISAmethod based on recombinant HA andNA proteins.
The H1N1 vaccine component of the vaccine was NC99, and im-
munity was assessed using homologousHA andNA reagents. Pre-
existing immunity against NC99H1HAwas found to be relatively
high at baseline, and the immunity increased greatly after vacci-
nation (24-fold) (Fig. 6A and E). Preexisting antibody levels
against theNC99N1were found to be low, and the antibody levels
did not increase significantly after vaccination (1.1-fold) (Fig. 6B
and E). The H3N2 component of the vaccine strains was A/Wyo-
ming/3/03. However, due to the lack of homologous reagents, we
usedHA andNA proteins of a closely relatedH3N2 strain, A/Pan-
ama/2007/99. The H3 baseline titer was lower than the baseline
titer of H1, and vaccination resulted in a 6.4-fold induction
(Fig. 6C and E). The N2 baseline titer was higher than the one for
N1, and the titer increased 2-fold upon vaccination (Fig. 6D and
E). IIV induced a significantly stronger immune response against
HA than against NA for both influenza A virus components of the
vaccine, with a P value of 0.0003 for H1N1 and a P value of 0.0240
for H3N2 (Fig. 6E).
The N1 NA contents of inactivated influenza virus vaccines
vary greatly. A possible reason for the low level of induction of
anti-NA antibodies compared to the level of induction of anti-HA
antibodies by IIV could be the amount of NA present in IIVs. We
therefore quantified the N1 NA content in current IIVs. First,
using the broadly N1-reactive monoclonal antibody (MAb) 4A5
(see Fig. S4 in the supplemental material), we performed a semi-
quantitativeWestern blot analysis of four 2013-2014 seasonal vac-
cines tomeasure their N1 contents. Three of four vaccines showed
robust levels of NA, while one vaccine, Flucelvax (Novartis), only
showed a very weak band (Fig. 7A). Interestingly, although the
dominant band was running between 50 and 80 kDa, we also
detected multiple and diverse higher-molecular-mass species in
the three egg-derived vaccines (Fig. 7A). We then quantified the
N1 NA content of the four tested vaccines using an ELISA-based
assay and linear regression. The highest N1 NA content was mea-
sured in Fluzone (10.5 g/vaccine dose), followed by Fluvirin
(5.0g/vaccine dose) and FluLaval (4.4g/vaccine dose). The cell
culture-derived Flucelvax appeared to have only minimal
amounts of NA (0.02 g/vaccine dose). Since we tested only one
cell culture-derived vaccine (the only one on the market as of
2014-2015), it is unclear whether the low N1 content of this vac-
cine is caused by the virus production method or by steps down-
stream in the production process.
DISCUSSION
Inactivated influenza virus vaccines—both seasonal and pandem-
ic—are standardized based on the amounts of the major surface
glycoproteinHA that they include (8). Consequently, only anHA-
based surrogate measure of protection, HA inhibition (HI) activ-
ity, is used to assess the efficacy of influenza virus vaccines (35).
Importantly, IIV only induces a relatively narrow immune re-
sponse, and protection is mostly limited to viral strains closely
related to the vaccine strain (4–6). The IIV-induced immune re-
sponse in humans against the NA is significantly weaker than the
response against the HA (9, 22, 29, 30, 31, 36). We have shown
FIG 6 Seasonal IIV vaccination is inefficient at inducing NA reactive anti-
bodies in humans. HA andNA reactivities of human pre- and postvaccination
sera from 12 individuals who received the 2004-2005 inactivated seasonal vac-
cine were determined. (A and B) The geometric mean H1 titer was relatively
high at baseline (~1,600) and was induced approximately 24-fold upon vacci-
nation (P 0.0001) (A), while the geometric mean N1 baseline titer was low
(~200) and did not increase upon vaccination (B). (C and D) The geometric
mean H3 baseline titer (~800) was lower than that of H1 and vaccination
induced a 6.4-fold induction (P 0.0003) (C), while the geometric mean N2
baseline titer was higher than that ofN1 and increased 2-fold upon vaccination
(P 0.0230) (D). (E) IIV induced significantly higher endpoint titers against
HA than against NA for both influenza A virus subtypes included in the vac-
cine (P 0.0003 for H1N1, and P 0.0240 for H3N2).
Wohlbold et al.
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here that in certain cases, no response against NA can be detected
at all, despite a high level of induction of antibodies against the
correspondingHA. There are several factors that could contribute
to the low immunogenicity of NA compared to that of HA. First,
NA seems to be inherently immunosubdominant to HA when
both antigens are administered in conjunction (22, 30, 31). Sec-
ond, HA is more abundant on the virus surface than NA (37), and
third, the NA could be lost to some extent during themanufactur-
ing of the vaccine. To investigate the third factor, we assessed the
N1 NA content of four licensed IIVs from the 2013-2014 season,
produced by three manufacturers. Interestingly, all egg-derived
vaccines had robust amounts of NA, while the cell culture-derived
preparation contained only minimal amounts of N1. However,
since most licensed IIVs are derived from eggs (including the one
used for measuring human HA and NA titers as described above
[Fig. 6]), we dismiss a low NA content of vaccines as an explana-
tion for the low immunogenicity.
It has beenhypothesized that robust immune responses against
NA could contribute to protection against both homologous and
heterologous virus strains. To study the protective potential of
NA, we decided to test recombinant-NA-based immunogens in
mice. Purified recombinant NA was chosen due to the reasons
outlined above. Also, we wanted to ensure that protection in
these experiments was solely based on anti-NA immunity with-
out interference from immunity to other influenza virus proteins.
Interestingly, we found robust protection against homologous
challenge, comparable to that conferred by vaccination with inac-
tivated whole virus. Complete protection against morbidity and
mortality was observed even at high challenge doses when the
vaccine was given intranasally. Intramuscular vaccination still re-
sulted in full protection against mortality at high challenge doses,
but significant weight loss was observed, suggesting that mucosal
immunity can play an important role in NA-based protection. In
contrast to inactivated whole-virus vaccines, vaccination with NA
antigens did not result in sterilizing immunity, but it reduced lung
titers drastically, which is in line with the results of historic studies
in humans and animal models (10, 20). However, it should be
noted that two vaccinations with whole-virus vaccines were nec-
essary to induce sterilizing immunity. Since passive transfer of sera
from vaccinated mice protected naive mice from challenge, we
conclude that humoral immunity is sufficient for protection, al-
though a contribution of cellular immunity to NA-based protec-
tion cannot be ruled out.
Finally, we also assessed the breadth of NA-based protection.
Previous studies have identified an epitope that is highly con-
served among influenza A virus NAs (38). An antibody that rec-
ognized this epitopewas also effective in inhibiting the influenza B
virus neuraminidase (38, 39). However, the antibody has rela-
tively low effective concentrations compared to those of specific
anti-NA antibodies (15, 38, 39), and it is unknown whether simi-
lar antibodies against the same epitope can be induced by natural
infection or vaccination with influenza virus vaccines. We found
that vaccination with NAs N3 to N9 did not induce protective
immunity againstH1N1orH3N2 challenge. Also,N1 antigens did
not protect against challenge withN2-expressing viruses (and vice
versa). However, we saw limited heterologous (within the sub-
type) cross-protection for influenza A viruses. N1 antigens from
an early human isolate gave partial protection against challenge
FIG 7 The amounts of Cal09 NA contained in seasonal IIVs from the 2013-2014 influenza season varied. (A) Five-fold serial dilutions of 4 IIVs recommended
for the 2013-2014 influenza season were analyzed for N1 NA content via Western blot assay. Membranes were blotted with 4A5 (an MAb specific for N1 NA).
Each panel represents a separately runWestern blot of a unique vaccine brand. Dilutions of baculovirus-expressed Cal09 rN1 (left blot in each panel) of known
concentrations were run alongside each vaccine sample on the same gel. Dilutions of vaccines and amounts of standard are displayed above the gels, and the
names of the vaccines are displayed below. (B) Quantities of N1 NA per adult vaccine dose (0.5 ml) as measured by ELISA. Bar graphs show themean values and
standard deviation (SD).
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with a pandemic H1N1 strain and an H5N1 strain, both of which
carry avian-type N1 NAs that are phylogenetically distinct from
the human N1 lineage (9). This finding is supported by reports
of N1 cross-reactive monoclonal antibodies (15) and cross-
protection against H5N1 induced by H1N1 exposure (13, 14, 16,
17, 40). We also found full cross-protection in terms of mortality
for the N2 immunogen whenmice were challenged with anH3N2
strain that had 14 years of drift. It is of note that this cross-
protection was limited to lower challenge doses; no cross-
protection was observed for either N1 or N2 at high challenge
doses. Interestingly, cross-protection was solid for influenza B vi-
ruses; an NA immunogen from Yam88 B (Yamagata lineage) was
able to fully protect against two Victoria lineage strains. Impor-
tantly, the influenza B virusNAhas not diverged into two lineages,
as has the influenza B virus HA, which may partially explain the
good cross-reactivity.
In conclusion, NA-based immunity is able to provide robust
protection against homologous influenza virus infection in mice.
Cross-protection seems to be confined within the same subtype,
with no intersubtypic protection displayed, as seen withHA stalk-
reactive antibodies (29, 41). However, subtype-specific cross-
reactive antibodies may have the potential to contribute to pro-
tection against drifted seasonal viruses in cases where the vaccine
is mismatched, as in the current 2014-2015 season (42). Further-
more, strong N1- and N2-based immunity might be beneficial in
the case of a new pandemic virus thatmay carry a heterologousN2
or N1 NA, such as H2N2 or H5N1. The current seasonal IIV is
suboptimal in inducing robust immunity against NA. To achieve
better induction of NA immunity, a number of strategies could be
developed. NA could be renderedmore immunogenic by present-
ing it in the context of a novel HA globular head domain or chi-
mericHA towhich humans are naive (7, 22). Alternatively, the IIV
could be supplemented with purified NA or purified NA could be
given as an extra vaccine in addition to the IIV. Our data support
the notion that NA-based immunity is an important part of the
multifaceted immune response that protects against influenza dis-
ease. Utilizing the full potential of NA as a vaccine antigen may
improve and broaden the protective efficacy of influenza virus
vaccines, especially in the fight against influenzaB virus infections.
MATERIALS AND METHODS
Viruses and cells.Madin Darby canine kidney (MDCK) cells were grown
in complete Dulbecco’s modified Eagle’s medium (DMEM; Life Technol-
ogies) supplemented with antibiotics (100 units/ml penicillin–100 g/ml
streptomycin [Pen-Strep]; Gibco) and 10% fetal bovine serum (FBS; Hy-
Clone). Sf9 insect cells were grown in TNM-FH insect medium (Gemini
Bioproducts) supplemented with antibiotics (Pen-Strep) and 10% FBS,
andHigh Five (BTI-TN-5B1-4 subclone; Vienna Institute of BioTechnol-
ogy [41]) cells were grown in serum-free SFX-insect medium (HyClone)
supplemented with antibiotics (Pen-Strep). Influenza viruses (A/Puerto
Rico/8/34 [PR8; H1N1], HK68/X-31 [H3N2, PR8 internal genes and HA
and NA from A/Hong Kong/1/68], A/Netherlands/602/09 [NL09; pan-
demic H1N1], Phil82/X-79 [H3N2, PR8 internal genes and HA and NA
from A/Philippines/2/82], low-pathogenicity A/Vietnam/1203/04
[VN04; H5N1, PR8 internal genes and HA and NA from A/Vietnam/
1203/04 with polybasic cleavage site of the HA deleted], B/Victoria/2/87
[Vic87], B/Yamagata/16/88 [Yam88 B], and B/Malaysia/2506/04
[Mal04]) were grown in 8- to 10-day-old embryonated chicken eggs, and
titers were determined onMDCK cells in the presence of tosyl phenylala-
nyl chloromethyl ketone (TPCK)-treated trypsin. For ELISAs, influenza
viruses were concentrated through a 30% buffered sucrose cushion by
ultracentrifugation (Beckman L7-65 ultracentrifuge with SW-28 rotor at
25,000 rpm). Recombinant baculoviruses expressing neuraminidases
were generated as described previously and grown in Sf9 cells (28).
Recombinant proteins. Recombinant neuraminidase proteins (PR8
N1, HK68/X-31 N2, A/Texas/36/91 N1, A/New Caledonia/20/99 N1,
A/California/4/09 [Cal09] N1, A/Panama/2007/99 N2, Yam88 B NA,
A/swine/Missouri/4296424/06 N3, A/mallard/Sweden/24/02 N4, A/mal-
lard/Sweden/86/03 N5, A/mallard/Netherlands/1/99 N6, A/mallard/Inte-
rior Alaska/10BM01929/10 N7, A/mallard/Sweden/50/02 N8, and A/An-
hui/1/13 N9) were expressed in High Five cells and purified from cell
culture supernatants as described previously (26, 27). Briefly, cultures
were infected with recombinant baculoviruses at a multiplicity of infec-
tion (MOI) of 10. Supernatants were then harvested by low-speed centrif-
ugation 72 h postinfection and were purified via Ni-nitrilotriacetic acid
(NTA) resin (Qiagen) using a published protocol (26).
Vaccination and challenge studies. Six- to 8-week-old female BALB/c
mice were used for all vaccination and challenge studies. For standard
challenge experiments, mice (n 5 to 10) were anesthetized (0.15 mg/kg
of body weight ketamine and 0.03 mg/kg xylazine intraperitoneally) and
received recombinant NA adjuvanted with poly(I · C) [5g rNA and 5g
poly(I · C) in 50 l of PBS intranasally [i.n.] plus 5 g rNA and 5 g
poly(I · C) in 50l of PBS intramuscularly (i.m.)], bovine serum albumin
(BSA) adjuvanted with poly(I · C) [5g BSA and 5g poly(I · C) in 50l
of PBS i.n. plus 5g BSA and 5g poly(I · C) in 50l of PBS i.m.; negative
control], or matched inactivated whole- or split-virus vaccines (1 g in-
tramuscularly in 50 l of PBS; positive control); in most cases, a mis-
matched rNA from a different subtype was used as an additional negative
control [5 g rNA and 5 g poly(I · C) in 50 l of PBS i.n. plus 5 g rNA
and 5 g poly(I · C) in 50 l of PBS i.m.]. A boost using the same formu-
lations and routes was given at 3 weeks postprime. Animals used for i.n.
versus i.m. experiments were vaccinated twice with 5g of rNA plus 5g
of poly(I · C) either i.n. or i.m. at the same intervals and volumes as
described above. At 4 weeks postboost, animals were anesthetized and
intranasally challenged with 25 (i.n. vs i.m. experiment), 10 (homolo-
gous), or 5 (heterologous) murine 50% lethal doses (mLD50) of virus in
50l of PBS. An exceptionwas the Yam88B experiment, wheremicewere
challenged with a sublethal dose (1.1 106 PFU) of virus due to the low
pathogenicity of the isolate.Weightwasmonitored for a period of 14 days.
Animals used for lung titer experiments were vaccinated via the i.n.
and i.m. routes as described above, and lungs were harvested 3 and 6 days
postchallenge. The lungs were then homogenized using a BeadBlaster 24
(Benchmark) homogenizer, and the virus lung titer was measured using a
plaque assay in MDCK cells.
For the passive transfer experiments, animals (HK68/X-31 rN2, BSA,
and positive-control groups) were anesthetized and terminally bled. Se-
rum was harvested and transferred into naive mice (200 l per mouse
intraperitoneally; n  5 per group). At 2 h posttransfer, the mice were
challenged with 5 mLD50 of HK68/X-31 virus as described above. Weight
was monitored for a period of 14 days.
All animal procedures were performed in accordance with protocols
approved by the Icahn School of Medicine at Mount Sinai Institutional
Animal Care and Use Committee.
Human sera. Human sera were obtained from a clinical trial per-
formed at the University of Bergen, Norway, with the 2004-2005 tri-
valent influenza vaccine Fluarix (GlaxoSmithKline) (A/Caledonia/
20/99 [H1N1], A/Wyoming/3/03 [H3N2], and B/Jiangsu/10/03) (28).
Serum samples were taken 14 days postvaccination. The trial was ap-
proved by the regional ethics committee (REK Vest, approval number
170-04) and the Norwegian Medicines Agency.
Mouse serum preparation. Sera collected in all vaccination studies
were stored long term at20°C until use. In all serological assays, serum
samples from individual mice within an experimental group were pooled
and inactivated by heating in a 56°C water bath for 1 h.
ELISA. For mouse serum ELISAs, plates (Immulon 4 HBX; Thermo
Scientific) were coated overnight with 5g/ml (50l per well) of concen-
trated influenza virus in coating buffer (carbonate-bicarbonate buffer,
Wohlbold et al.
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pH 9.4) at 4°C. Plates were then blocked using 3%milk in PBS containing
0.1% Tween 20 (TPBS) for 1 h at room temperature. Serum samples were
diluted in steps of 1:3 starting with a 1:100 dilution in 1% TPBS. Plates
with the serum samples were then incubated for 1 h at room temperature.
After three washes with TPBS (100 l/well for each wash), plates were
incubated for another hour at room temperature with a horseradish per-
oxidase (HRP)-labeled anti-mouse antibody (1:3,000; GE Healthcare)
and developed using SigmaFast OPD (o-phenylenediamine dihydrochlo-
ride; 100 l per well [Sigma]) after another round of extensive washing.
Plates were developed for 10 min, stopped with 3 M hydrochloric acid
(HCl) (50l/well), and read at an optical density of 490 nm (OD490) on a
Synergy 4 (BioTek) plate reader.
The procedure for human ELISAs was similar, but the followingmod-
ifications were made. Plates were coated with recombinant HA or NA
(2g/ml, 50l perwell), and blockingwas performed inTPBS containing
3% goat serum and 0.5% milk (GM-TPBS). GM-TPBS was also used for
making serum dilutions (steps of 1:2 starting with 1:100) and for diluting
the HRP-labeled anti-human IgG secondary antibody (1:3,000; Sigma).
Endpoint titers were calculated by using the value for the blank plus 3
times the standard deviation as the cutoff. The results are shown as fold
induction, calculated by dividing postvaccination endpoint titers by pre-
vaccination endpoint titers as described previously (33).
Enzyme-linked lectin assay (ELLA) to determine neuraminidase in-
hibition. In order to determine the ideal virus concentration to be used in
the NI assay, NA assays were first performed for all virus stocks. In brief,
flat-bottom nonsterile Immulon 4 HBX 96-well plates (Thermo Scien-
tific) were coated (carbonate-bicarbonate coating buffer, pH 9.4) with
150l of fetuin (Sigma) at a concentration of 50g/l and refrigerated at
4°C overnight. The coating buffer was discarded, and wells were blocked
for 1 h at room temperature with 200 l blocking solution (PBS contain-
ing 5% BSA). While plates were being blocked, virus stocks were serially
diluted 1:2 in a separate sterile flat-bottom 96-well tissue culture plate
(Sigma) using PBS containing 1%BSA. Dilutions weremade horizontally
across the plate, starting with undiluted stock and ensuring that the final
volume in all wells was 150 l. After blocking for 1 h, the plates were
washed 6 times using TPBS (225 l/well). After the last wash, plates were
forcefully tapped on clean paper towels to ensure that no residual wash
buffer remained (this technique was repeated for all subsequent wash
steps). One hundred-microliter amounts of the viral dilutions were trans-
ferred in parallel to the fetuin-coated plates, after which the plates were
incubated at 37°C for 2 h. The plates were again washed 6 times using
TPBS (225l/well), and a secondary solution of peanut agglutinin (PNA)
conjugated to HRP (PNA-HRP; Sigma) at a concentration of 5 g/ml in
PBS was added to the plates (100 l/well). After a 1-h 45-min incubation
in the dark, the plates were again washed 6 times using TBPS (225l/well)
and developed with 100 l SigmaFast OPD. The developing process was
stopped after 7minwith 3MHCl, and the reactionmixture was read at an
absorbance of 490 nm with a Synergy H1 hybrid multimode microplate
reader (BioTek). In order to determine the optimal concentration of virus
to use for subsequent NI assays, ELISA data from the NA assay for each
virus were plotted in GraphPad Prism 6 software and fit to a nonlinear
curve. In this way, a 50% effective concentration (EC50)-like value could
be obtained (in this case, the concentration of virus at which half the
maximal OD reading was obtained). Two times this concentration
(2 EC50) was used for subsequent NI assays.
To perform NI assays, ELISA plates were coated and blocked in a
fashion identical to the method used for the NA assay. While plates were
blocking,mouse serum samples were serially diluted 1:2 in separate sterile
flat-bottom 96-well tissue culture plates using PBS, starting with a 1:50
dilution and ensuring that the final volume in all wells was 75 l. Virus
stocks were diluted with PBS containing 1% BSA to the 2 EC50 concen-
tration determined to be optimal. After virus was added to the antibody
plates (75 l/well), the plates were briefly tapped (for mixing) and incu-
bated at room temperature for 1 h 40 min. Immediately before the incu-
bation time expired, the blocked plates were washed 6 times using TPBS
(225 l/well). One hundred-microliter amounts of the virus/serum mix-
turewere transferred in parallel to the fetuin-coated plates, after which the
plateswere incubated at 37°C for 2 h. The plateswere againwashed 6 times
using TPBS (225l/well), and a secondary solution of PNA-HRP (Sigma)
at a concentration of 5g/ml in PBSwas added to the plates (100l/well).
The rest of the NI assay protocol was identical to that of the NA assay. The
values obtained from the plate readerwere divided by the average value for
virus-only control wells and then multiplied by a factor of 100 to obtain
the NA activity. Percent inhibition was calculated by subtracting the NA
activity from 100.
Western blot and quantitative ELISA analysis. Four different brands
of FDA-licensed influenza vaccines intended for use in the 2013-2014
flu season were obtained from the Mount Sinai Hospital pharmacy,
local pharmacies, or directly from the manufacturer. The trade names
of the vaccines (with the respective lot number, H1N1 strain included,
and manufacturer in parentheses) were as follows: Fluvirin (13472P,
A/Christchurch/16/2010; Novartis Vaccines and Manufacturers), Flucel-
vax (161281, A/Brisbane/10/2010; Novartis Vaccines and Manufactur-
ers), Fluzone (UH953AA, A/California/07/2009 X-179A; Sanofi Pasteur),
and FluLaval (597FZ, A/California/07/2009; ID Biomedical Corporation
of Quebec). All of the brands obtained are trivalent, egg-derived vaccines
except for Flucelvax, which is produced in a suspension of MDCK cells.
Using a small initial volume of each vaccine, 5-fold serial dilutions were
prepared in PBS, mixed with an equal volume of 2 Laemmli buffer with
2%beta-mercaptoethanol (BME), andheated for 30min at 100°C. Twelve
microliters of each dilution was loaded on polyacrylamide gels (5-to-20%
gradient; Bio-Rad). As a standard control, equivalent-volume dilutions of
baculovirus-expressed, purifiedCal09 rN1,with a known starting concen-
tration of 0.672 mg/ml (as measured by Bradford protein assay; Bio-Rad)
were loaded on the same gel, adjacent to the vaccine dilutions (each
unique vaccine was run on a separate gel, however). After transferring for
40 min at 0.11 A using a semidry transfer apparatus (Owl Semi-dry Elec-
troblotting System; Thermo Fisher), the blots were washed 3 times for
3 min in PBS (all subsequent wash steps were done in this way) and
blocked with 3%milk in TBPS for 1 h at room temperature. The blocking
solution was removed, a primary antibody solution of MAb 4A5 (1:3,000
in 1% milk TBPS) was added to the blots in enough volume so they were
completely submerged, and the blots were incubated for 1 h at room
temperature. MAb 4A5 is an antibody that broadly binds to N1 NA (Fig.
S4). After removing the primary antibody solution and washing, the blots
were incubated for 1 h at room temperature with an HRP-labeled anti-
mouse antibody (1:6,000; GE Healthcare). The secondary solution was
removed, the blots were washed, and developing solutionwas added (1ml
of enhanced luminol reagent plus 1ml of oxidizing agent [Western Light-
ning ECL]; PerkinElmer). After ~30 s in the developing solution, the blots
were developed on standard autoradiography film (HyBlot Cl; Denville
Scientific) using a 1-min exposure time (SRX-101A; Konica Minolta).
In order to approximately quantify the amount ofN1NA contained in
the vaccine formulations, flat-bottomnonsterile Immulon 4HBX 96-well
plates (Thermo Scientific) were coated with triplicate serial 1:2 dilutions
of each vaccine sample in coating buffer (see above), starting with a 1:2
dilution and diluting horizontally across the plate. As a standard, wells
were coated with baculovirus-expressed, purified Cal09 rN1 in an identi-
cal fashion, starting with a known concentration of 16 g/ml. The plates
were incubated at 4°C overnight. The general mouse ELISA protocol (as
detailed above)was performed, except that the primary antibody usedwas
MAb 4A5, added at a constant concentration of 3 g/ml (in 3% milk
TPBS, 100 l/well). ELISA data were transferred to Microsoft Excel, the
average of each triplicate reading was calculated, and points (dilution
versusOD reading) were plotted in order to determine the portion of each
sample curve that was most linear (using R-squared regression analysis).
For the Cal09 rN1 curve, this best-fit linear equation was used to calculate
the unknownN1 concentrations of the 4 vaccine formulations. The values
were averaged and are reported in Fig. 7B.
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